497 results
8-K
EX-99.1
LLY
Lilly(Eli) & Co
30 Apr 24
Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum
7:04am
extent, improvements in the cost of production.
In Q1 2024, research and development expenses increased 27% to $2.52 billion, or 29% of revenue, driven … and benefit costs.
In Q1 2024, the company recognized acquired in-process research and development (IPR&D) charges of $110.5 million compared
424B2
3uf4h8d6v0v
8 Feb 24
Prospectus for primary offering
4:51pm
424B2
oitau4demfg
7 Feb 24
Prospectus for primary offering
8:12am
8-K
EX-99.1
2vdxwug n0q0zan5wy
6 Feb 24
Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance
7:04am
8-K
EX-99.1
i9egdxmj920
2 Nov 23
Lilly Reports Third-Quarter 2023 Financial Results, Highlights Strong Sales Growth and Business Development Activity
7:02am
CORRESP
xku9syd6e
26 Oct 23
Correspondence with SEC
12:00am
SC TO-T
EX-99
sv81vrk1p05ya
13 Oct 23
Third party tender offer statement
6:52am
SC TO-C
EX-99.1
skiyuky1
3 Oct 23
Information about tender offer
4:30pm
8-K
EX-99.1
u25y t0ml8xqxldamp
8 Aug 23
Lilly Reports Second-Quarter 2023 Financial Results, Highlights Accelerating Revenue Growth and Key Pipeline Advancements
7:01am
SC TO-T
EX-99
f7p8i94jyx1enuqt2w3x
13 Jul 23
Third party tender offer statement
8:01am